Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years [Phase 2]

View source ↗

Summary

Phase 2 immunogenicity and safety study of GSK's herpes zoster vaccine in adults 50+ completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Herpes Zoster Vaccine (herpes zoster vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 2 | Status: COMPLETED | Results posted: 2017-12-12